DR. REDDY'S LABORATORIES-ADR (RDY) Fundamental Analysis & Valuation

NYSE:RDY • US2561352038

Current stock price

13.67 USD
+0.09 (+0.66%)
At close:
13.5637 USD
-0.11 (-0.78%)
After Hours:

This RDY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. RDY Profitability Analysis

1.1 Basic Checks

  • In the past year RDY was profitable.
  • In the past year RDY had a positive cash flow from operations.
  • Each year in the past 5 years RDY has been profitable.
  • RDY had a positive operating cash flow in each of the past 5 years.
RDY Yearly Net Income VS EBIT VS OCF VS FCFRDY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20B 40B 60B

1.2 Ratios

  • With an excellent Return On Assets value of 10.62%, RDY belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
  • The Return On Equity of RDY (16.03%) is better than 88.48% of its industry peers.
  • RDY has a Return On Invested Capital of 13.03%. This is amongst the best in the industry. RDY outperforms 91.62% of its industry peers.
  • RDY had an Average Return On Invested Capital over the past 3 years of 15.26%. This is above the industry average of 13.11%.
Industry RankSector Rank
ROA 10.62%
ROE 16.03%
ROIC 13.03%
ROA(3y)13.25%
ROA(5y)10.88%
ROE(3y)18.65%
ROE(5y)15.68%
ROIC(3y)15.26%
ROIC(5y)13.95%
RDY Yearly ROA, ROE, ROICRDY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • With an excellent Profit Margin value of 16.82%, RDY belongs to the best of the industry, outperforming 89.01% of the companies in the same industry.
  • RDY's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 19.62%, RDY belongs to the top of the industry, outperforming 87.96% of the companies in the same industry.
  • In the last couple of years the Operating Margin of RDY has grown nicely.
  • With a decent Gross Margin value of 66.88%, RDY is doing good in the industry, outperforming 74.35% of the companies in the same industry.
  • RDY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.62%
PM (TTM) 16.82%
GM 66.88%
OM growth 3Y9.42%
OM growth 5Y4.7%
PM growth 3Y19.59%
PM growth 5Y8.42%
GM growth 3Y2.12%
GM growth 5Y0.39%
RDY Yearly Profit, Operating, Gross MarginsRDY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

6

2. RDY Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), RDY is creating some value.
  • The number of shares outstanding for RDY remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, RDY has more shares outstanding
  • The debt/assets ratio for RDY is higher compared to a year ago.
RDY Yearly Shares OutstandingRDY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
RDY Yearly Total Debt VS Total AssetsRDY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100B 200B 300B 400B

2.2 Solvency

  • RDY has an Altman-Z score of 5.75. This indicates that RDY is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 5.75, RDY is in the better half of the industry, outperforming 75.92% of the companies in the same industry.
  • RDY has a debt to FCF ratio of 3.17. This is a good value and a sign of high solvency as RDY would need 3.17 years to pay back of all of its debts.
  • RDY's Debt to FCF ratio of 3.17 is amongst the best of the industry. RDY outperforms 90.05% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that RDY is not too dependend on debt financing.
  • RDY has a Debt to Equity ratio (0.03) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 3.17
Altman-Z 5.75
ROIC/WACC1.28
WACC10.17%
RDY Yearly LT Debt VS Equity VS FCFRDY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100B 200B 300B

2.3 Liquidity

  • A Current Ratio of 1.85 indicates that RDY should not have too much problems paying its short term obligations.
  • RDY's Current ratio of 1.85 is on the low side compared to the rest of the industry. RDY is outperformed by 68.59% of its industry peers.
  • A Quick Ratio of 1.35 indicates that RDY should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.35, RDY is not doing good in the industry: 71.73% of the companies in the same industry are doing better.
  • The current and quick ratio evaluation for RDY is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.35
RDY Yearly Current Assets VS Current LiabilitesRDY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B 200B 250B

4

3. RDY Growth Analysis

3.1 Past

  • RDY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.81%.
  • RDY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 23.62% yearly.
  • The Revenue has grown by 11.06% in the past year. This is quite good.
  • The Revenue has been growing by 13.26% on average over the past years. This is quite good.
EPS 1Y (TTM)3.81%
EPS 3Y33.55%
EPS 5Y23.62%
EPS Q2Q%-14.29%
Revenue 1Y (TTM)11.06%
Revenue growth 3Y14.86%
Revenue growth 5Y13.26%
Sales Q2Q%4.44%

3.2 Future

  • The Earnings Per Share is expected to decrease by -1.17% on average over the next years.
  • RDY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.09% yearly.
EPS Next Y-7.77%
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%
EPS Next 5YN/A
Revenue Next Year6.7%
Revenue Next 2Y5.09%
Revenue Next 3Y6.55%
Revenue Next 5Y7.09%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
RDY Yearly Revenue VS EstimatesRDY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100B 200B 300B 400B
RDY Yearly EPS VS EstimatesRDY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20 40 60

5

4. RDY Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 19.25, RDY is valued on the expensive side.
  • Based on the Price/Earnings ratio, RDY is valued cheaper than 84.29% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.42. RDY is valued slightly cheaper when compared to this.
  • A Price/Forward Earnings ratio of 22.92 indicates a rather expensive valuation of RDY.
  • RDY's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. RDY is cheaper than 77.49% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of RDY to the average of the S&P500 Index (22.24), we can say RDY is valued inline with the index average.
Industry RankSector Rank
PE 19.25
Fwd PE 22.92
RDY Price Earnings VS Forward Price EarningsRDY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • RDY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. RDY is cheaper than 86.39% of the companies in the same industry.
  • 77.49% of the companies in the same industry are more expensive than RDY, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 58.07
EV/EBITDA 11.5
RDY Per share dataRDY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • RDY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.82
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%

4

5. RDY Dividend Analysis

5.1 Amount

  • RDY has a yearly dividend return of 0.60%, which is pretty low.
  • Compared to an average industry Dividend Yield of 0.73, RDY pays a better dividend. On top of this RDY pays more dividend than 89.01% of the companies listed in the same industry.
  • With a Dividend Yield of 0.60, RDY pays less dividend than the S&P500 average, which is at 1.81.
Industry RankSector Rank
Dividend Yield 0.6%

5.2 History

  • The dividend of RDY decreases each year by -19.44%.
  • RDY has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-19.44%
Div Incr Years0
Div Non Decr Years0
RDY Yearly Dividends per shareRDY Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

5.3 Sustainability

  • RDY pays out 11.54% of its income as dividend. This is a sustainable payout ratio.
  • RDY's earnings and Dividend Rate are declining. This means the current dividend is most likely not sustainable.
DP11.54%
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%
RDY Yearly Income VS Free CF VS DividendRDY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20B 40B
RDY Dividend Payout.RDY Dividend Payout, showing the Payout Ratio.RDY Dividend Payout.PayoutRetained Earnings

RDY Fundamentals: All Metrics, Ratios and Statistics

DR. REDDY'S LABORATORIES-ADR

NYSE:RDY (4/24/2026, 8:05:33 PM)

After market: 13.5637 -0.11 (-0.78%)

13.67

+0.09 (+0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21
Earnings (Next)05-12
Inst Owners52.17%
Inst Owner Change4.02%
Ins Owners1.23%
Ins Owner Change0%
Market Cap11.38B
Revenue(TTM)346.82B
Net Income(TTM)57.72B
Analysts67.56
Price Target14.57 (6.58%)
Short Float %2.49%
Short Ratio6.7
Dividend
Industry RankSector Rank
Dividend Yield 0.6%
Yearly Dividend0.08
Dividend Growth(5Y)-19.44%
DP11.54%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.63%
Min EPS beat(2)-8.52%
Max EPS beat(2)-6.74%
EPS beat(4)1
Avg EPS beat(4)-3.93%
Min EPS beat(4)-8.52%
Max EPS beat(4)2.77%
EPS beat(8)4
Avg EPS beat(8)-0.94%
EPS beat(12)8
Avg EPS beat(12)6.66%
EPS beat(16)10
Avg EPS beat(16)7.01%
Revenue beat(2)0
Avg Revenue beat(2)-2.69%
Min Revenue beat(2)-3.88%
Max Revenue beat(2)-1.51%
Revenue beat(4)1
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-3.88%
Max Revenue beat(4)1%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)7
Avg Revenue beat(12)1.24%
Revenue beat(16)9
Avg Revenue beat(16)1.2%
PT rev (1m)-4.38%
PT rev (3m)-2.35%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)0.01%
EPS NY rev (1m)-0.79%
EPS NY rev (3m)-1.52%
Revenue NQ rev (1m)-0.43%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)1.52%
Valuation
Industry RankSector Rank
PE 19.25
Fwd PE 22.92
P/S 3.13
P/FCF 58.07
P/OCF 18.24
P/B 2.98
P/tB 4.38
EV/EBITDA 11.5
EPS(TTM)0.71
EY5.19%
EPS(NY)0.6
Fwd EY4.36%
FCF(TTM)0.24
FCFY1.72%
OCF(TTM)0.75
OCFY5.48%
SpS4.37
BVpS4.59
TBVpS3.12
PEG (NY)N/A
PEG (5Y)0.82
Graham Number8.56235 (-37.36%)
Profitability
Industry RankSector Rank
ROA 10.62%
ROE 16.03%
ROCE 17.14%
ROIC 13.03%
ROICexc 16.05%
ROICexgc 25.11%
OM 19.62%
PM (TTM) 16.82%
GM 66.88%
FCFM 5.38%
ROA(3y)13.25%
ROA(5y)10.88%
ROE(3y)18.65%
ROE(5y)15.68%
ROIC(3y)15.26%
ROIC(5y)13.95%
ROICexc(3y)19.62%
ROICexc(5y)17.62%
ROICexgc(3y)25.36%
ROICexgc(5y)22.59%
ROCE(3y)21.22%
ROCE(5y)19.86%
ROICexgc growth 3Y6.58%
ROICexgc growth 5Y2.58%
ROICexc growth 3Y0.6%
ROICexc growth 5Y-0.12%
OM growth 3Y9.42%
OM growth 5Y4.7%
PM growth 3Y19.59%
PM growth 5Y8.42%
GM growth 3Y2.12%
GM growth 5Y0.39%
F-Score4
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 3.17
Debt/EBITDA 0.13
Cap/Depr 211.61%
Cap/Sales 11.76%
Interest Coverage 16.55
Cash Conversion 68.09%
Profit Quality 32%
Current Ratio 1.85
Quick Ratio 1.35
Altman-Z 5.75
F-Score4
WACC10.17%
ROIC/WACC1.28
Cap/Depr(3y)179.81%
Cap/Depr(5y)161.03%
Cap/Sales(3y)9.33%
Cap/Sales(5y)8.68%
Profit Quality(3y)47.43%
Profit Quality(5y)60.48%
High Growth Momentum
Growth
EPS 1Y (TTM)3.81%
EPS 3Y33.55%
EPS 5Y23.62%
EPS Q2Q%-14.29%
EPS Next Y-7.77%
EPS Next 2Y-8.97%
EPS Next 3Y-1.17%
EPS Next 5YN/A
Revenue 1Y (TTM)11.06%
Revenue growth 3Y14.86%
Revenue growth 5Y13.26%
Sales Q2Q%4.44%
Revenue Next Year6.7%
Revenue Next 2Y5.09%
Revenue Next 3Y6.55%
Revenue Next 5Y7.09%
EBIT growth 1Y1.53%
EBIT growth 3Y25.68%
EBIT growth 5Y18.58%
EBIT Next Year11.24%
EBIT Next 3Y7.07%
EBIT Next 5Y9.87%
FCF growth 1Y-62.42%
FCF growth 3Y9.92%
FCF growth 5Y-12.7%
OCF growth 1Y-18.43%
OCF growth 3Y18.21%
OCF growth 5Y9.24%

DR. REDDY'S LABORATORIES-ADR / RDY Fundamental Analysis FAQ

What is the ChartMill fundamental rating of DR. REDDY'S LABORATORIES-ADR (RDY) stock?

ChartMill assigns a fundamental rating of 6 / 10 to RDY.


What is the valuation status for RDY stock?

ChartMill assigns a valuation rating of 5 / 10 to DR. REDDY'S LABORATORIES-ADR (RDY). This can be considered as Fairly Valued.


How profitable is DR. REDDY'S LABORATORIES-ADR (RDY) stock?

DR. REDDY'S LABORATORIES-ADR (RDY) has a profitability rating of 8 / 10.


What are the PE and PB ratios of DR. REDDY'S LABORATORIES-ADR (RDY) stock?

The Price/Earnings (PE) ratio for DR. REDDY'S LABORATORIES-ADR (RDY) is 19.25 and the Price/Book (PB) ratio is 2.98.


How financially healthy is DR. REDDY'S LABORATORIES-ADR?

The financial health rating of DR. REDDY'S LABORATORIES-ADR (RDY) is 6 / 10.